Search for Clinical Trial Results
Hemorrhagic Fever - 110 Studies Found
Status | Study |
Completed |
Study Name: Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults Condition: Hemorrhagic Fever, Ebola Date: 2015-09-29 Interventions: Biological: HPIV3-EbovZ GP Vaccine Administered intranasally by a VaxINator device |
Completed |
Study Name: Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea Condition: Hemorrhagic Fever, Ebola Date: 2015-01-12 Interventions: Other: Convalescent Plasma Patients will be treated with plasma from recovered EVD patients. |
Completed |
Study Name: Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever Condition:
Date: 2012-05-14 Interventions:
|
Completed |
Study Name: Experimental Ebola Vaccine Trial Condition:
Date: 2003-11-04 Interventions: Drug: VRC-EBODNA012-00-VP |
Completed |
Study Name: Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America Condition:
Date: 2010-08-20 Interventions:
|
Enrolling by invitation |
Study Name: Ribavirin for Hemorrhagic Fever With Renal Syndrome Condition: Hemorrhagic Fever With Renal Syndrome Date: 2008-02-13 Interventions: Drug: Ribavirin 7 Day multiple dosing regime based on weight and dosage day |
Withdrawn |
Study Name: Ribavirin for Hemorrhagic Fever With Renal Syndrome in Germany Condition: Hemorrhagic Fever With Renal Syndrome Date: 2009-03-24 Interventions: Drug: Virazole (Ribavirin) Duration of Subject Participati |
Active, not recruiting |
Study Name: Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever Condition: Hemorrhagic Fever With Renal Syndrome Date: 2014-04-14 Interventions:
|
Completed |
Study Name: Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines Condition: Hemorrhagic Fever With Renal Syndrome Date: 2011-12-23 Interventions: Biological: Vaccine/device combination for prevention of HFRS PUUV DNA Vaccine, 2.0mg/ml TDS-IM injectio |
Recruiting |
Study Name: Diagnostic of Puumala Virus Infection in France Condition:
|